MinhTri Nguyen, MD
@minhtrimd.bsky.social
Medical Oncologist at Stanford | Certified Coach | Researcher in emotional intelligence | Always learning, and finding good food. My opinions are my own.
#Medsky #Oncosky
#Medsky #Oncosky
Pinned
MinhTri Nguyen, MD
@minhtrimd.bsky.social
· Nov 23
James Stoller, MD & MinhTri Nguyen, MD - Developing Leaders in Healthcare - Phronesis: Practical Wisdom for Leaders with Scott Allen
Dr. Stoller is Chairman of the Education Institute at Cleveland Clinic. He holds the Jean Wall Bennett Professorship of Medicine at Cleveland Clinic Lerner College of Medicine and the Samson Global Le...
www.buzzsprout.com
My interview on developing leaders in healthcare with James Stoller, MD and Scott Allen, Ph.D.
#leadership #medsky
#leadership #medsky
Sometimes Oncology just doesn’t follow guidelines. I use Primum when I hit those moments. Thoughtful, fast answers from peers who know their stuff. If you're curious:
Great for fellows and those already in practice.
Great for fellows and those already in practice.
Primum
A digital platform helping patients receive better care closer to home. We connect oncologists with sub-specialists to discuss their most complex cancer cases.
app.primum.co
April 24, 2025 at 5:24 PM
Sometimes Oncology just doesn’t follow guidelines. I use Primum when I hit those moments. Thoughtful, fast answers from peers who know their stuff. If you're curious:
Great for fellows and those already in practice.
Great for fellows and those already in practice.
Reposted by MinhTri Nguyen, MD
Is surgery always necessary for invasive breast cancer? 🩺🔍
New research is challenging the status quo and exploring less invasive paths for treatment. A must-read for oncology professionals.
Read more: ascopost.com/news/april-2...
#BreastCancer #CancerResearch #ASCO2025
New research is challenging the status quo and exploring less invasive paths for treatment. A must-read for oncology professionals.
Read more: ascopost.com/news/april-2...
#BreastCancer #CancerResearch #ASCO2025
April 7, 2025 at 2:01 PM
Is surgery always necessary for invasive breast cancer? 🩺🔍
New research is challenging the status quo and exploring less invasive paths for treatment. A must-read for oncology professionals.
Read more: ascopost.com/news/april-2...
#BreastCancer #CancerResearch #ASCO2025
New research is challenging the status quo and exploring less invasive paths for treatment. A must-read for oncology professionals.
Read more: ascopost.com/news/april-2...
#BreastCancer #CancerResearch #ASCO2025
No generational judgement—disheartening to see burnout at all. Especially in
In a field that clearly still holds joy for those that practice. The landscape is not what it used to be & we’ve trained to be nimble with medical decision—not staffing, prior auth, or EMR burden.
In a field that clearly still holds joy for those that practice. The landscape is not what it used to be & we’ve trained to be nimble with medical decision—not staffing, prior auth, or EMR burden.
Trends in Well-Being and Burnout Among U.S. Oncologists: Challenges and Solutions @ascocancer.bsky.social @acochran12733.bsky.social @jrgralow.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social
January 30, 2025 at 6:20 AM
No generational judgement—disheartening to see burnout at all. Especially in
In a field that clearly still holds joy for those that practice. The landscape is not what it used to be & we’ve trained to be nimble with medical decision—not staffing, prior auth, or EMR burden.
In a field that clearly still holds joy for those that practice. The landscape is not what it used to be & we’ve trained to be nimble with medical decision—not staffing, prior auth, or EMR burden.
Reposted by MinhTri Nguyen, MD
The FDA has approved trastuzumab deruxtecan (T-DXd) for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer based on DESTINY-Breast06 trial results. #BreastCancer #Oncology ascopost.com/news/january...
January 28, 2025 at 5:58 PM
The FDA has approved trastuzumab deruxtecan (T-DXd) for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer based on DESTINY-Breast06 trial results. #BreastCancer #Oncology ascopost.com/news/january...
Reposted by MinhTri Nguyen, MD
Thank you for sharing your incredible immigrant story from Vietnam - to selling strawberries on the streets of Maine - one of our best fellows at @clevelandclinic.bsky.social and now as an oncologist in @Stanford medicine www.linkedin.com/posts/minhtr...
@minhtrimd.bsky.social inspiring!
@minhtrimd.bsky.social inspiring!
MinhTri Nguyen, MD on LinkedIn: From strawberries to stethoscopes: lessons in humanity from a future…
Thank you to Kevin Pho, M.D. for publishing my story. And Kim Downey for encouraging me to submit my personal statement “as is”. As I continue to practice in…
www.linkedin.com
January 17, 2025 at 12:19 PM
Thank you for sharing your incredible immigrant story from Vietnam - to selling strawberries on the streets of Maine - one of our best fellows at @clevelandclinic.bsky.social and now as an oncologist in @Stanford medicine www.linkedin.com/posts/minhtr...
@minhtrimd.bsky.social inspiring!
@minhtrimd.bsky.social inspiring!
I was born in the mountains of 🇻🇳. At 5 my parents sought the land of opportunity 🇺🇸. This Dec our family reunited in 🇻🇳. My country has changed and so have we. Change = opportunity.
From my Fam to yours: Happy new years! With the change, I hope you also find your opportunities to grow.
From my Fam to yours: Happy new years! With the change, I hope you also find your opportunities to grow.
December 29, 2024 at 8:25 AM
I was born in the mountains of 🇻🇳. At 5 my parents sought the land of opportunity 🇺🇸. This Dec our family reunited in 🇻🇳. My country has changed and so have we. Change = opportunity.
From my Fam to yours: Happy new years! With the change, I hope you also find your opportunities to grow.
From my Fam to yours: Happy new years! With the change, I hope you also find your opportunities to grow.
A bit late on the announcement but thrilled to be selected for the Stanford Physician Leadership Certificate Program! I look forward to learning and enhancing my leadership skills and leadership theory.
I accept! (-ed before the deadline) :)
#leadership
I accept! (-ed before the deadline) :)
#leadership
December 22, 2024 at 5:13 PM
A bit late on the announcement but thrilled to be selected for the Stanford Physician Leadership Certificate Program! I look forward to learning and enhancing my leadership skills and leadership theory.
I accept! (-ed before the deadline) :)
#leadership
I accept! (-ed before the deadline) :)
#leadership
Reposted by MinhTri Nguyen, MD
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX
#MedSky #SABCS24
#MedSky #SABCS24
December 11, 2024 at 2:08 PM
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX
#MedSky #SABCS24
#MedSky #SABCS24
I’ve found many apps to be extremely useful as a fellow and practicing oncologist.
For a quick (usually less than 48 hrs) curbside consult to an Oncologist, Hematologist, RadOnc, Pharmacist etc. I’ve been using Primum. You can also ask anonymously. See link.
#oncsky #cansky #medsky
For a quick (usually less than 48 hrs) curbside consult to an Oncologist, Hematologist, RadOnc, Pharmacist etc. I’ve been using Primum. You can also ask anonymously. See link.
#oncsky #cansky #medsky
Primum
A digital platform helping patients receive better care closer to home. We connect oncologists with sub-specialists to discuss their most complex cancer cases.
app.primum.co
December 12, 2024 at 4:01 PM
Reposted by MinhTri Nguyen, MD
We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.
Why aren’t more oncologists using MRD tests like Signatera or Guardant Reveal to proactively treat NSCLC before PD shows up on imaging especially in later treatment lines? www.jto.org/article/S155...
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.
www.jto.org
December 8, 2024 at 1:06 PM
We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.
Wrote this haiku before #ASHaiku for #ASH24 but I’d like to shamelessly repost for submission. In response to @oligoclonalband.bsky.social ‘s cooly made Neuro-skirt.
December 2, 2024 at 10:35 PM
Wrote this haiku before #ASHaiku for #ASH24 but I’d like to shamelessly repost for submission. In response to @oligoclonalband.bsky.social ‘s cooly made Neuro-skirt.
Reposted by MinhTri Nguyen, MD
Day 2 of #BLADDR24
Dr Rob Jones
Case metastatic UCa
Treatment sequencing in the era of combination therapies
Emphasizes that first-line therapy with EV and P is poised to become the new SoC
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr Rob Jones
Case metastatic UCa
Treatment sequencing in the era of combination therapies
Emphasizes that first-line therapy with EV and P is poised to become the new SoC
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 28, 2024 at 10:56 AM
Day 2 of #BLADDR24
Dr Rob Jones
Case metastatic UCa
Treatment sequencing in the era of combination therapies
Emphasizes that first-line therapy with EV and P is poised to become the new SoC
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr Rob Jones
Case metastatic UCa
Treatment sequencing in the era of combination therapies
Emphasizes that first-line therapy with EV and P is poised to become the new SoC
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
My interview on developing leaders in healthcare with James Stoller, MD and Scott Allen, Ph.D.
#leadership #medsky
#leadership #medsky
James Stoller, MD & MinhTri Nguyen, MD - Developing Leaders in Healthcare - Phronesis: Practical Wisdom for Leaders with Scott Allen
Dr. Stoller is Chairman of the Education Institute at Cleveland Clinic. He holds the Jean Wall Bennett Professorship of Medicine at Cleveland Clinic Lerner College of Medicine and the Samson Global Le...
www.buzzsprout.com
November 23, 2024 at 4:56 PM
My interview on developing leaders in healthcare with James Stoller, MD and Scott Allen, Ph.D.
#leadership #medsky
#leadership #medsky
@valdesan.bsky.social to the rescue! Oncology Vol 1 and 2 starter packs (links included in the packs)
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
November 23, 2024 at 7:06 AM
@valdesan.bsky.social to the rescue! Oncology Vol 1 and 2 starter packs (links included in the packs)
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
Reposted by MinhTri Nguyen, MD
Interesting case series (n=3) from Emory of patients with pretreated HER2+ and HER2-low MBC with severe hepatic impairment tolerating well and deriving clinical benefit from dose-reduced T-DXd. www.sciencedirect.com/science/arti...
Administration of Trastuzumab Deruxtecan in Metastatic Breast Cancer Patients with Severe Hepatic Impairment
Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic im…
www.sciencedirect.com
November 23, 2024 at 1:19 AM
Interesting case series (n=3) from Emory of patients with pretreated HER2+ and HER2-low MBC with severe hepatic impairment tolerating well and deriving clinical benefit from dose-reduced T-DXd. www.sciencedirect.com/science/arti...
Amazing. Imagine the next level: Incorporating such large language models into our EMR systems to provide suggested matched clinical trials in real time! These LLM are already being trialed and implemented for inbox management at some institutions. Anxiously hopeful. 🙏
'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social:
- 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking
- Retrieval identified 90% suitable trials
- 42% time-saving in matching a patient to a trial
Like, wow
#MedSky #OncSky #LCSM
www.nature.com/articles/s41...
- 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking
- Retrieval identified 90% suitable trials
- 42% time-saving in matching a patient to a trial
Like, wow
#MedSky #OncSky #LCSM
www.nature.com/articles/s41...
Matching patients to clinical trials with large language models - Nature Communications
Patient recruitment is challenging for clinical trials. Here, the authors introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models.
www.nature.com
November 19, 2024 at 1:49 AM
Amazing. Imagine the next level: Incorporating such large language models into our EMR systems to provide suggested matched clinical trials in real time! These LLM are already being trialed and implemented for inbox management at some institutions. Anxiously hopeful. 🙏
November 17, 2024 at 7:47 PM
Reposted by MinhTri Nguyen, MD
Voting in the ASCO Election is open now until December 3! Meet the candidates for the Board of Directors – Undesignated Member seat.
Learn more about each candidate, determine your voting eligibility, and make your voice heard at brnw.ch/21wOzu3
Learn more about each candidate, determine your voting eligibility, and make your voice heard at brnw.ch/21wOzu3
ASCO Election
ASCO Election
brnw.ch
November 12, 2024 at 3:48 PM
Voting in the ASCO Election is open now until December 3! Meet the candidates for the Board of Directors – Undesignated Member seat.
Learn more about each candidate, determine your voting eligibility, and make your voice heard at brnw.ch/21wOzu3
Learn more about each candidate, determine your voting eligibility, and make your voice heard at brnw.ch/21wOzu3